BUSINESS

• Japan Likely the Only Negative Growth Pharma Market in 2018-2022: IQVIA
  March 16, 2018

• Rohto Wins Japan Exclusive Rights to JT’s JAK Inhibitor in Ophthalmology Field
  March 16, 2018

• Ono Exercises Option to Ink New Autoimmune Disease Deal with Merus
  March 15, 2018

• Shionogi’s Single-Dose Flu Med Xofluza Hits Japan Shelves
  March 15, 2018

• Kaketsuken, Meiji-Kumamoto JV, Ink Deal on Share Transfer of New Company, with Completion Date Set on July 2
  March 15, 2018

• Re-Pricing Rule for Indication Expansions Mars I/O Development: MSD Japan Chief
  March 14, 2018

• Gilead Japan Rolling Up Its Sleeves for Foray into Oncology/Inflammation Market
  March 14, 2018

• Toyama Chemical Begins Patient Enrollment in Japan PIII Study of Avigan for SFTS
  March 13, 2018

• EA Pharma’s Livact Now Available in Thailand
  March 12, 2018

• Solifenacin Oral Suspension Approved in Europe for Pediatric NDO: Astellas
  March 12, 2018

• Costa Saroukos Tapped as Takeda’s Global CFO
  March 9, 2018

• Hiroo Ito Named New President of Actelion Pharmaceuticals Japan
  March 9, 2018

• Daiichi Sankyo’s ADC DS-8201 Enters Global PII Study for Colorectal Cancer
  March 9, 2018

• Aducanumab Trial Tweak Has No Impact on Probability of Success: Eisai CEO
  March 9, 2018

• Eisai Bags Up-to-US$5.76 Billion Lenvima Alliance with Merck
  March 9, 2018

• Foreign Drug Makers Increased Market Share to Over 60% among Top 20 Makers in 2017
  March 9, 2018

• Torii’s Futhan to Get 43.4% Price Cut in April, Urinorm 24.6%: Top 5 Product Survey
  March 8, 2018

• Insomnia Drug Lemborexant Hits PIII Goals in Sleep Disorders: Eisai
  March 8, 2018

• US FDA Approves Latuda for Pediatric Use in Bipolar I Depression: Sumitomo Dainippon
  March 8, 2018

• Yoshikazu Aoki Named as New Asahi Kasei Pharma President
  March 8, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 404
• 405
• 406
• 407
• 408
• 409
• 410
• 411
• 412
• …
• Next ›
• 最終 »